OPKO Health, Inc. logo OPK - OPKO Health, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 8
HOLD 4
SELL 1
STRONG
SELL
0
| PRICE TARGET: $2.87 DETAILS
HIGH: $4.00
LOW: $1.60
MEDIAN: $3.00
CONSENSUS: $2.87
UPSIDE: 125.98%

About OPKO Health, Inc. (https://www.opko.com)

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Key Executives

NAME TITLE DOB SALARY
Phillip Frost Chairman of the Board & CEO 1936 $1,454,000 USD
Elias Adam Zerhouni President & Vice Chairman of the Board 1951 $1,364,000 USD
Jane H. Hsiao Vice Chairman of the Board & Chief Technical Officer 1947 $1,364,000 USD
Steven D. Rubin Executive Vice President of Administration & Director 1960 $1,224,000 USD
Adam E. Logal Senior Vice President, Chief Financial Officer, Chief Accounting Officer & Treasurer 1978 $1,189,000 USD
Akhtar Ashfaq Senior Vice President of Clinical Research & Development and Medical Affairs - Opko Renal
Arie Gutman President of API 1954
Charles W. Bishop Chief Executive Officer of OPKO Renal 1952
Craig Allen Chief Executive Officer of Bioreference Health
Damien Burke Chief Executive Officer of EirGen Pharma
Gary J. Nabel Chief Information Officer & Director 1955
Giovanni Abbadessa Chief Medical Officer of ModeX
Hans Berner President of OPKO Health Iberoamerica
John R. Mascola Chief Scientific Officer of ModeX

Company Peers

Peer analysis pending, check back in 1-2 minutes.